Concepts (87)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Intensive Care Units | 6 | 2024 | 55 | 2.740 |
Why?
|
| Critical Care | 6 | 2024 | 25 | 2.670 |
Why?
|
| Critical Illness | 4 | 2023 | 31 | 1.110 |
Why?
|
| Anxiety | 3 | 2023 | 32 | 1.020 |
Why?
|
| Family | 3 | 2024 | 26 | 1.020 |
Why?
|
| Depression | 3 | 2023 | 113 | 0.960 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2023 | 54 | 0.750 |
Why?
|
| Sepsis | 2 | 2018 | 25 | 0.690 |
Why?
|
| Stress, Psychological | 1 | 2021 | 58 | 0.640 |
Why?
|
| Humans | 9 | 2024 | 5837 | 0.600 |
Why?
|
| Hospitals, Low-Volume | 1 | 2018 | 3 | 0.560 |
Why?
|
| Hospitals, High-Volume | 1 | 2018 | 3 | 0.560 |
Why?
|
| Immunocompromised Host | 1 | 2018 | 12 | 0.560 |
Why?
|
| Hospital Mortality | 1 | 2018 | 30 | 0.550 |
Why?
|
| Adult | 5 | 2022 | 1670 | 0.500 |
Why?
|
| Hospitalization | 2 | 2021 | 86 | 0.290 |
Why?
|
| Middle Aged | 3 | 2021 | 1775 | 0.240 |
Why?
|
| Aged | 3 | 2021 | 1860 | 0.240 |
Why?
|
| Male | 3 | 2021 | 3399 | 0.200 |
Why?
|
| Female | 3 | 2021 | 3346 | 0.200 |
Why?
|
| Policy | 1 | 2023 | 5 | 0.200 |
Why?
|
| Consensus | 1 | 2023 | 21 | 0.200 |
Why?
|
| Communication | 1 | 2023 | 20 | 0.200 |
Why?
|
| Sleep | 1 | 2024 | 88 | 0.190 |
Why?
|
| Pandemics | 1 | 2021 | 63 | 0.170 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 284 | 0.150 |
Why?
|
| Eosinophils | 1 | 2019 | 3 | 0.150 |
Why?
|
| Bacteremia | 1 | 2019 | 13 | 0.150 |
Why?
|
| Immunity, Innate | 1 | 2019 | 13 | 0.150 |
Why?
|
| Staphylococcus aureus | 1 | 2019 | 17 | 0.150 |
Why?
|
| Cytokines | 1 | 2019 | 63 | 0.140 |
Why?
|
| Staphylococcal Infections | 1 | 2019 | 30 | 0.140 |
Why?
|
| Serum Bactericidal Test | 1 | 2018 | 1 | 0.140 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2018 | 2 | 0.140 |
Why?
|
| Multilevel Analysis | 1 | 2018 | 4 | 0.140 |
Why?
|
| Odds Ratio | 1 | 2018 | 60 | 0.140 |
Why?
|
| Length of Stay | 1 | 2018 | 45 | 0.140 |
Why?
|
| Logistic Models | 1 | 2018 | 109 | 0.140 |
Why?
|
| Case-Control Studies | 1 | 2018 | 136 | 0.140 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 1034 | 0.110 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2013 | 1 | 0.100 |
Why?
|
| Antioxidant Response Elements | 1 | 2013 | 1 | 0.100 |
Why?
|
| Pulmonary Alveoli | 1 | 2013 | 6 | 0.100 |
Why?
|
| Oxidative Stress | 1 | 2013 | 25 | 0.100 |
Why?
|
| HIV-1 | 1 | 2013 | 74 | 0.090 |
Why?
|
| Animals | 2 | 2019 | 1349 | 0.050 |
Why?
|
| Promyelocytic Leukemia Zinc Finger Protein | 1 | 2019 | 1 | 0.040 |
Why?
|
| Interleukin-5 | 1 | 2019 | 1 | 0.040 |
Why?
|
| Interleukin-13 | 1 | 2019 | 2 | 0.040 |
Why?
|
| Antigens, CD1d | 1 | 2019 | 2 | 0.040 |
Why?
|
| Interleukin-33 | 1 | 2019 | 2 | 0.040 |
Why?
|
| Th2 Cells | 1 | 2019 | 4 | 0.040 |
Why?
|
| Th17 Cells | 1 | 2019 | 7 | 0.040 |
Why?
|
| Hypersensitivity | 1 | 2019 | 7 | 0.040 |
Why?
|
| Neutrophils | 1 | 2019 | 31 | 0.040 |
Why?
|
| Lung | 1 | 2019 | 31 | 0.040 |
Why?
|
| Pulmonary Edema | 1 | 2019 | 13 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2019 | 103 | 0.040 |
Why?
|
| Netherlands | 1 | 2018 | 21 | 0.040 |
Why?
|
| ROC Curve | 1 | 2018 | 34 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 122 | 0.040 |
Why?
|
| Asthma | 1 | 2019 | 35 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 62 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 125 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 222 | 0.030 |
Why?
|
| Mice | 1 | 2019 | 465 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2018 | 406 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2018 | 411 | 0.030 |
Why?
|
| United States | 1 | 2018 | 502 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2018 | 584 | 0.030 |
Why?
|
| Quinones | 1 | 2013 | 1 | 0.020 |
Why?
|
| NAD(P)H Dehydrogenase (Quinone) | 1 | 2013 | 1 | 0.020 |
Why?
|
| Claudins | 1 | 2013 | 1 | 0.020 |
Why?
|
| Tight Junction Proteins | 1 | 2013 | 1 | 0.020 |
Why?
|
| Sulfoxides | 1 | 2013 | 3 | 0.020 |
Why?
|
| Isothiocyanates | 1 | 2013 | 3 | 0.020 |
Why?
|
| Anticarcinogenic Agents | 1 | 2013 | 3 | 0.020 |
Why?
|
| Occludin | 1 | 2013 | 4 | 0.020 |
Why?
|
| Thiocyanates | 1 | 2013 | 4 | 0.020 |
Why?
|
| Zonula Occludens-1 Protein | 1 | 2013 | 6 | 0.020 |
Why?
|
| RNA Interference | 1 | 2013 | 10 | 0.020 |
Why?
|
| Rats, Transgenic | 1 | 2013 | 7 | 0.020 |
Why?
|
| Glutathione | 1 | 2013 | 9 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2013 | 31 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2013 | 87 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2013 | 167 | 0.020 |
Why?
|
| Rats | 1 | 2013 | 282 | 0.020 |
Why?
|